For research use only. Not for therapeutic Use.
NU2058（Cat No.:I002053）is a selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK1 and CDK2. This compound is widely used in cancer research to study the regulation of cell cycle progression and the potential therapeutic targeting of CDKs in cancer treatments. By inhibiting CDK1 and CDK2, NU2058 interferes with cell cycle control, leading to cell cycle arrest and apoptosis in cancer cells. Its high specificity and effectiveness make it a valuable tool in exploring cancer biology, with a focus on identifying novel strategies for tumor suppression and drug development.
| Catalog Number | I002053 |
| CAS Number | 161058-83-9 |
| Synonyms | O6-(Cyclohexylmethyl)guanine |
| Molecular Formula | C12H17N5O |
| Purity | ≥95% |
| Target | CDK |
| Solubility | DMSO: ≥ 32 mg/mL |
| Storage | Keep in dark place,Sealed in dry,2-8°C |
| IC50 | 17μM (CDK2), 26μM (CDK1) |
| IUPAC Name | 6-(cyclohexylmethoxy)-7H-purin-2-amine |
| InChI | InChI=1S/C12H17N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H3,13,14,15,16,17) |
| InChIKey | MWGXGTJJAOZBNW-UHFFFAOYSA-N |
| SMILES | C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)N |
| Reference | </br>1:The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Harrison LR, Ottley CJ, Pearson DG, Roche C, Wedge SR, Dolan ME, Newell DR, Tilby MJ.Biochem Pharmacol. 2009 May 15;77(10):1586-92. doi: 10.1016/j.bcp.2009.02.018. Epub 2009 Mar 5. PMID: 19426695 </br>2:Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Rigas AC, Robson CN, Curtin NJ.Oncogene. 2007 Dec 6;26(55):7611-9. Epub 2007 Jun 18. PMID: 17599054 |
